Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis

Journal of Virology

Volumn 87, Issue 6, 2013, Pages 3484-3501

  Berchtold, Susanne ^a   Lampe, Johanna ^a   Weiland, Timo ^a   Smirnow, Irina ^a   Schleicher, Sabine ^a   Handgretinger, Rupert ^a   Kopp, Hans Georg ^a   Reiser, Jeanette ^a   Stubenrauch, Frank ^a   Mayer, Nora ^a   Malek, Nisar P ^a   Bitzer, Michael ^a   Lauer, Ulrich M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOSINE DEAMINASE; FLUCYTOSINE; HYBRID PROTEIN; MEASLES VACCINE VIRUS; ONCOLYTIC VIRUS; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; SUPER CYTOSINE DEAMINASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; IFIT1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IFIT1 GENE; INNATE IMMUNITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOMA CELL; SUICIDE GENE; TUMOR CELL DESTRUCTION; UPREGULATION; VIROGENESIS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MEASLES VIRUS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; HUMANS; INTERFERON-BETA; MEASLES VIRUS; ONCOLYTIC VIRUSES; STAT1 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

MLCS; MLOWN;

EID: 84876303245     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02106-12     Document Type: Article

References (47)

1. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, III, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, III, Letson GD, McGarry SV, ODonnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J, National Comprehensive Cancer Network Soft Tissue Sarcoma Panel. 2010. Soft tissue sarcoma. J. Natl. Compr. Canc. Netw. 8:630-674.
2. Demicco EG, Maki RG, Lev DC, Lazar AJ. 2012. New therapeutic targets in soft tissue sarcoma. Adv. Anat. Pathol. 19:170-180.
3. Russell SJ, Peng KW, Bell JC. 2012. Oncolytic virotherapy. Nat. Biotechnol. 30:658-670. doi:10.1038/nbt.2287.
4. Cattaneo R, Miest T, Shashkova EV, Barry MA. 2008. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 6:529-540.
5. Kubo T, Shimose S, Matsuo T, Fujimori J, Sakaguchi T, Yamaki M, Shinozaki K, Woo SL, Ochi M. 2011. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J. Orthop. Res. 29:795-800. doi:10.1002/jor.21307.
6. Paglino JC, van den Pol AN. 2011. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J. Virol. 85:9346-9358.
7. He S, Li P, Chen CH, Bakst RL, Chernichenko N, Yu YA, Chen N, Szalay AA, Yu Z, Fong Y, Wong RJ. 2012. Effective oncolytic vaccinia therapy for human sarcomas. J. Surg. Res. 175:e53- e60. doi:10.1016/j.jss .2011.11.1030.
8. Lettieri CK, Hingorani P, Kolb EA. 2012. Progress of oncolytic viruses in sarcomas. Expert Rev. Anticancer Ther. 12:229-242.
9. Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. 2006. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44: 1465-1477.
10. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ.2002. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62:4656-4662.
11. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK. 2001. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97:3746-3754.
12. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ, Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. 2010. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70:875-882.
13. Lech PJ, Russell SJ. 2010. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev. Vaccines 9:1275-1302.
14. Takeuchi O, Akira S. 2008. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 20:17-22.
15. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5-Triphosphate RNA is the ligand for RIG-I. Science 314:994-997.
16. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G, Juranek S, Kato H, Kawai T, Poeck H, Fitzgerald KA, Takeuchi O, Akira S, Tuschl T, Latz E, Ludwig J, Hartmann G. 2009. Recognition of 5triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31:25-34.
17. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, Robb N, Vreede F, Barclay W, Fodor E, Reis e Sousa C. 2010. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 140: 397-408.
18. Darnell JE, Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
19. Childs K, Stock N, Ross C, Andrejeva J, Hilton L, Skinner M, Randall R, Goodbourn S. 2007. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 359:190-200.
20. Childs KS, Andrejeva J, Randall RE, Goodbourn S. 2009. Mechanism of mda-5 inhibition by paramyxovirus V proteins. J. Virol. 83:1465-1473.
21. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dötsch C, Christiansen G, Billeter MA. 1995. Rescue of measles viruses from cloned cDNA. EMBO J. 14:5773-5784.
22. Seya T. 2011. Addendum to Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-β-inducing potential [Mol. Immunol. 48(4) (2011) 497-504]. Mol. Immunol. 48:1589-1590.
23. Takaki H, Watanabe Y, Shingai M, Oshiumi H, Matsumoto M, Seya T. 2011. Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-β-inducing potential. Mol. Immunol. 48:497-504.
24. Shingai M, Ebihara T, Begum NA, Kato A, Honma T, Matsumoto K, Saito H, Ogura H, Matsumoto M, Seya T. 2007. Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J. Immunol. 179:6123-6133.
25. Childs K, Randall R, Goodbourn S. 2012. Paramyxovirus V proteins interact with the RNA helicase LGP2 to inhibit RIG-I-dependent interferon induction. J. Virol. 86:3411-3421.
26. Pfaller CK, Conzelmann KK. 2008. Measles virus V protein is a decoy substrate for IkappaB kinase alpha and prevents Toll-like receptor 7/9- mediated interferon induction. J. Virol. 82:12365-12373.
27. Caignard G, Guerbois M, Labernardiére JL, Jacob Y, Jones LM, Infectious Mapping Project Wild I-MAPF, Tangy F, Vidalain PO. 2007. Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling. Virology 368:351-362.
28. Ramachandran A, Parisien JP, Horvath CM. 2008. STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition. J. Virol. 82:8330-8338.
29. Graepler F, Lemken ML, Wybranietz WA, Schmidt U, Smirnow I, Gross CD, Spiegel M, Schenk A, Graf H, Lauer UA, Vonthein R, Gregor M, Armeanu S, Bitzer M, Lauer UM. 2005. Bifunctional chimeric SuperCD suicide gene-YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J. Gastroenterol. 11:6910-6919.
30. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, Jund R, Mehtali M. 2000. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60:3813-3822.
31. Longley DB, Harkin DP, Johnston PG. 2003. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3:330-338.
32. Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK, Kalle C, Ungerechts G. 2012. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther. 19:181-191. doi:10.1038/cgt.2011.75.
33. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs Arch. Pharmacol. 162:480-483.
34. Spearman C. 1908. The method of right and wrong cases (constant stimuli) without Gauss's formulae. Br. J. Psychol. 2:227-242. doi:10.1111 /j.2044-8295.1908.tb00176.x.
35. Anderson BD, Nakamura T, Russell SJ, Peng KW. 2004. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64:4919-4926.
36. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
37. Reiser J, Hurst J, Voges M, Krauss P, Münch P, Iftner T, Stubenrauch F. 2011. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 85:11372-11380.
38. Berghäll H, Sirén J, Sarkar D, Julkunen I, Fisher PB, Vainionpää R, Matikainen S. 2006. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. Microbes Infect. 8:2138-2144.
39. Ikegame S, Takeda M, Ohno S, Nakatsu Y, Nakanishi Y, Yanagi Y. 2010. Both RIG-I and MDA5 RNA helicases contribute to the induction of alpha/ beta interferon in measles virus-infected human cells. J. Virol. 84: 372-379.
40. Plumet S, Herschke F, Bourhis JM, Valentin H, Longhi S, Gerlier D. 2007. Cytosolic 5triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. PLoS One 2:e279. doi:10.1371/journal.pone.0000279.
41. Fensterl V, Sen GC. 2011. The ISG56/IFIT1 gene family. J. Interferon Cytokine Res. 31:71-78.
42. Wang C, Pflugheber J, Sumpter R, Jr, Sodora DL, Hui D, Sen GC, Gale, M, Jr. 2003. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 77:3898-3912.
43. Terenzi F, Saikia P, Sen GC. 2008. Interferon-inducible protein, P56, inhibits HPVDNAreplication by binding to the viral protein E1.EMBOJ. 27:3311-3321.
44. Pichlmair A, Lassnig C, Eberle CA, Górna MW, Baumann CL, Burkard TR, Bürckstümmer T, Stefanovic A, Krieger S, Bennett KL, Rülicke T, Weber F, Colinge J, Müller M, Superti-Furga G. 2011. IFIT1 is an antiviral protein that recognizes 5-triphosphate RNA. Nat. Immunol. 12:624-630. doi:10.1038/ni.2048.
45. Liikanen I, Monsurrà V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D, Colombatti M, Hemminki A. 2011. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol. Ther. 19:1858-1866. doi:10.1038/mt.2011.144.
46. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q, Heisig M, Thamm D, Stritzker J, Macneill A, Szalay AA. 2012. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 7:e37239. doi:10.1371/journal.pone.0037239.
47. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. 2006. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 66: 7694-7700.